

To: Rose Edmonds[redmonds@theranos.com]; Paul Patel[ppatel@theranos.com]; Kwesi Mercurius[kmercurius@theranos.com]; Kathryn Rommel[KRommel@theranos.com]; Prasad Gawande[pgawande@theranos.com]; Douglas Matje[dmatje@theranos.com]; Caitlin Ortega[cortega@theranos.com]
Cc: Adam Rosendorff[arosendorff@theranos.com]; Xinwei Sam Gong[xgong@theranos.com]
From: Nicholas Haase
Sent: Sat 8/31/2013 6:11:02 PM
Importance: Normal
Subject: RE: GC assay
Received: Sat 8/31/2013 6:11:04 PM

In addition to Rose's comments, we just received pathological samples last night. These are only known to be pathological for a single analyte; therefore, we are going to screen these to see if they are pathological for any additional analytes.

Nick

-----Original Message-----

From: Rose Edmonds
Sent: Saturday, August 31, 2013 10:13 AM
To: Paul Patel; Nicholas Haase; Kwesi Mercurius; Kathryn Rommel; Prasad Gawande; Douglas Matje; Caitlin Ortega
Cc: Adam Rosendorff; Xinwei Sam Gong
Subject: RE: GC assay

As of right now none of our assays are completely through validation including clinical sample testing with fingerstick. We began venous testing on the new predilution protocols yesterday (Friday) for chem 18 and will continue today. I can try to prioritize doing samples with matched fingerstick today after I start the first set. Prioritizing clinical sample testing will slow down non-clinical validation of non-chem 18 assays but I am assuming that completing these clinicals is priority. Please let me know if that is not the case. Thanks.

Rose Edmonds
Development Scientist
Theranos, Inc
1601 South California
Palo Alto, CA, 94304
Phone: (650) 470-6152

PRIVILEGED AND CONFIDENTIAL COMMUNICATION IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which it is addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.
Theranos, Inc, 650-838-9292 www.theranos.com

-----Original Message-----

From: Paul Patel

Sent: Saturday, August 31, 2013 6:29 AM

To: Rose Edmonds; Nicholas Haase; Kwesi Mercurius; Kathryn Rommel; Prasad Gawande; Douglas Matje; Caitlin Ortega

Cc: Adam Rosendorff; Xinwei Sam Gong

Subject: FW: GC assay

Dear Team,

Can you give me an update so that I can respond? I know we have had quite a lot on non-clinical validation activities but not clear on the number of assays that are on the completed validation list that includes the clinical portion and the micro-sampling (assuming FS). Thanks

Paul

-----Original Message-----

From: Elizabeth Holmes

Sent: Saturday, August 31, 2013 1:17 AM

To: Paul Patel; Nicholas Haase; Xinwei Sam Gong

Cc: Daniel Young; Samartha Anekal; Sunny Balwani

Subject:

Let me know total number of GC micro-sample assays that have completed validation as of tomorrow (Advia and other platforms)